Immunic, Inc. | WebDisclosure

Basculer en Français

8296	Companies
114899	Keywords
55318	Articles
62453	Press releases

Home
Companies
Immunic, Inc.

BRIEF

published on 03/07/2024 at 12:35, 8 months 14 days ago

Immunic, Inc. annonce sa participation aux prochaines conférences scientifiques et investisseurs

Immunic, Inc. Maladies Auto-immunes Conférence Des Investisseurs Conférence Scientifique Inflammatoire Chronique
BRIEF

published on 03/07/2024 at 12:35, 8 months 14 days ago

Immunic, Inc. Announces Participation in Upcoming Investor and Scientific Conferences

Investor Conference Immunic, Inc. Autoimmune Diseases Scientific Conference Chronic Inflammatory
PRESS RELEASE

published on 03/07/2024 at 12:30, 8 months 14 days ago

Immunic to Participate in Investor and Scientific Conferences in March
Immunic, Inc. (Nasdaq: IMUX) announces participation in investor and scientific conferences in March, presenting abstracts and posters showcasing their clinical pipeline of therapies for inflammatory and autoimmune diseases

Investor Conference Biotechnology Clinical Pipeline Scientific Conference Immunic Inc
PRESS RELEASE

published on 02/29/2024 at 12:30, 8 months 21 days ago

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Immunic presents data from phase 2 CALLIPER and CALVID-1 trials of vidofludimus calcium at ACTRIMS Forum 2024. Positive results on serum neurofilament levels and EBV reactivation

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 Trials ACTRIMS Forum
BRIEF

published on 02/29/2024 at 12:30, 8 months 21 days ago

Immunic, Inc. Presents Phase 2 Trial Data on Vidofludimus Calcium at ACTRIMS 2024 Forum

ACTRIMS Forum 2024 Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 Trials
BRIEF

published on 02/29/2024 at 12:30, 8 months 21 days ago

Immunic, Inc. présente les données des essais de Phase 2 sur le Vidofludimus Calcium au Forum ACTRIMS 2024

Sclérose En Plaques Immunic Vidofludimus Calcium Essais De Phase 2 Forum ACTRIMS 2024
BRIEF

published on 02/22/2024 at 12:30, 8 months 28 days ago

Immunic, Inc. annonce ses résultats financiers annuels 2023 et une mise à jour corporative

Immunic, Inc. Résultats Financiers Annuels Maladies Inflammatoires Sclérose En Plaques Thérapies Orales
BRIEF

published on 02/22/2024 at 12:30, 8 months 28 days ago

Immunic, Inc. announces its 2023 annual financial results and corporate update

Immunic, Inc. Annual Financial Results Inflammatory Diseases Multiple Sclerosis Oral Therapies
PRESS RELEASE

published on 02/22/2024 at 12:30, 8 months 28 days ago

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Immunic, Inc. reports year end 2023 financial results and provides corporate update, including strengthened balance sheet and upcoming clinical milestones. Webcast scheduled for February 22, 2024

Financial Results Webcast Corporate Update Immunic Inc. Clinical Milestones
PRESS RELEASE

published on 02/15/2024 at 12:30, 9 months 6 days ago

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Immunic, Inc. to announce financial results and corporate update for the year ended December 31, 2023. Webcast on February 22, 2024, at 8:00 am ET

Financial Results Webcast Corporate Update Immunic Inc. Clinical Pipeline

1 2 ... 4

Accesswire

Published on 11/21/2024 at 13:00, 18 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 18 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 18 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 18 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 18 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 12:35, 43 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 3 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 11 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 18 minutes ago

Holding(s) in Company
Published on 11/21/2024 at 11:30, 1 hour 48 minutes ago

APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 20 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 20 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 6 hours 20 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 17 hours 10 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 17 hours 58 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE